Pharmacologic Approach to Management of Clostridium difficile Infection

Clostridium difficile is a gram-positive, anaerobic, spore-forming bacterium that is the leading cause of nosocomial infections in hospitals in the United States. Critically ill patients are at high risk for C. difficile infection (CDI) and face potentially detrimental effects, including prolonged hospitalization, risk of recurrent disease, complicated surgery, and death. CDI requires a multidisciplinary approach to decrease hospital transmission and improve treatment outcomes. This article briefly reviews the current literature and guideline recommendations for treatment and prevention of CDI, with a focus on antibiotic treatment considerations including dosing, routes of administration, efficacy data, adverse effects, and monitoring parameters.

• Publication year

  2019

• Venue

  Critical Care Nursing Quarterly

• Publication date

  2019-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/CNQ.0000000000000232PMID 30507659
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury.

  2021cited by this paper
• Metronidazole

  2019cited by this paper
• Fecal Microbiota Transplantation for Primary Clostridium difficile Infection.

  2018cited by this paper
• Clostridium difficile – From Colonization to Infection

  2018cited by this paper
• Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).

  2018cited by this paper
• Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children.

  2017cited by this paper
• Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin Treatment for Recurrent Clostridium difficile Infection: An Open-Label, Randomized Controlled Trial

  2017cited by this paper
• Effect of Oral Capsule– vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection: A Randomized Clinical Trial

  2017cited by this paper
• Vancomycin Taper and Pulse Regimen With Careful Follow-up for Patients With Recurrent Clostridium difficile Infection

  2017cited by this paper
• Revised Estimates for the Number of Human and Bacteria Cells in the Body

  2016cited by this paper
• Risk Factors for Systemic Vancomycin Exposure Following Administration of Oral Vancomycin for the Treatment of Clostridium difficile Infection

  2015cited by this paper
• Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection

  2015cited by this paper
• The Addition of Intravenous Metronidazole to Oral Vancomycin is Associated With Improved Mortality in Critically Ill Patients With Clostridium difficile Infection.

  2015cited by this paper
• Burden of Clostridium difficile infection in the United States.

  2015cited by this paper
• Colonization With Toxinogenic C. difficile Upon Hospital Admission, and Risk of Infection: A Systematic Review and Meta-Analysis

  2015cited by this paper
• Clostridium difficile infection.

  2015cited by this paper
• Vancomycin Enemas as Adjunctive Therapy for Clostridium difficile Infection

  2015cited by this paper
• Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.

  2014cited by this paper
• Decreasing Clostridium difficile Infections by an Antimicrobial Stewardship Program That Reduces Moxifloxacin Use

  2014cited by this paper
• Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison.

  2014cited by this paper
• Community-acquired Clostridium difficile infection: an increasing public health threat

  2014cited by this paper
• Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection.

  2014cited by this paper
• ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury

  2014cited by this paper
• Duodenal infusion of donor feces for recurrent Clostridium difficile.

  2013cited by this paper
• Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections

  2013cited by this paper
• Image of the month: “butterfly” effect, or mirror image, caused by a coiled esophageal manometry catheter.

  2013cited by this paper
• Risk Factors of Fecal Toxigenic or Non-Toxigenic Clostridium difficile Colonization: Impact of Toll-Like Receptor Polymorphisms and Prior Antibiotic Exposure

  2013cited by this paper
• Meta-Analysis of Antibiotics and the Risk of Community-Associated Clostridium difficile Infection

  2013cited by this paper
• An overview of fecal microbiota transplantation: techniques, indications, and outcomes.

  2013cited by this paper
• Clostridium difficile-Associated Diarrhea and Proton Pump Inhibitor Therapy: A Meta-Analysis

  2012cited by this paper
• Metronidazole-Induced Encephalopathy in a Patient with End-Stage Liver Disease

  2012cited by this paper
• Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain.

  2012cited by this paper
• Risk of Clostridium difficile Infection With Acid Suppressing Drugs and Antibiotics: Meta-Analysis

  2012cited by this paper
• Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin

  2012cited by this paper
• Metronidazole-Induced Neurotoxicity Developed in Liver Cirrhosis

  2012cited by this paper
• Probiotics for the Prevention of Clostridium difficile–Associated Diarrhea

  2012cited by this paper
• Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.

  2012cited by this paper
• Systemic absorption of oral vancomycin in patients with Clostridium difficile infection

  2011cited by this paper
• Fidaxomicin versus vancomycin for Clostridium difficile infection.

  2011cited by this paper
• Treating Clostridium difficile infection with fecal microbiota transplantation.

  2011cited by this paper
• Toxin B is essential for virulence of Clostridium difficile

  2009cited by this paper
• Clinical Review of the Management of Fulminant Clostridium difficile Infection

  2008cited by this paper
• Antimicrobial-associated risk factors for Clostridium difficile infection.

  2008cited by this paper
• Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain.

  2007cited by this paper
• A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity.

  2007cited by this paper
• Successful use of feedback to improve antibiotic prescribing and reduce Clostridium difficile infection: a controlled interrupted time series.

  2007cited by this paper
• Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive "bundle" approach.

  2007cited by this paper
• Bacterial diarrhea in persons with HIV infection, United States, 1992-2002.

  2005cited by this paper
• Clostridium difficile colitis

  2004cited by this paper
• Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital.

  2004cited by this paper
• Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease

  2002cited by this paper
• Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature.

  2002cited by this paper
• Risk factors for Clostridium difficile infection.

  1998cited by this paper
• Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro.

  1995cited by this paper
• Ten Years of Prospective Clostridium difficile-Associated Disease Surveillance and Treatment at the Minneapolis VA Medical Center, 1982–1991

  1994cited by this paper
• Clostridium difficile colitis.

  1994cited by this paper
• Clostridium difficile infection associated with antineoplastic chemotherapy: a review.

  1993cited by this paper
• Relapsing clostridium difficile enterocolitis cured by rectal infusion of homologous faeces.

  1983cited by this paper
• Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis.

  1958cited by this paper

• Management of Clostridioides difficile Infection.

  2019cites this paper